Healthcare provider profile · identity verified

Constance Jacob, APRN

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WICHITA, KS · NPI 1639729726

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Constance Jacob, APRN received $57,327.21 in general payments during 2025 across 303 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 82.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 18 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Fanapt, Invega Sustenna, Rexulti, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vraylar by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Invega Sustenna by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$57,327.21

303 reported records · 13 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$47,458.49	82.8%	111	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$7,248.52	12.6%	28	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$614.93	1.1%	38	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$563.87	1.0%	41	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$413.54	0.7%	26	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$316.08	0.6%	18	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$253.44	0.4%	11	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$150.05	0.3%	13	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$127.57	0.2%	7	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$80.09	0.1%	4	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$46.69	0.1%	3	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$36.65	0.1%	2	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$17.29	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$41,786.00	30
Consulting Fee	$6,055.50	5
Food and Beverage	$5,428.41	240
Travel and Lodging	$4,057.30	28

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$47,458.49	111	2025
Source payment records 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.88 · Open Payments source 2025-01-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.67 · Open Payments source 2025-01-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.63 · Open Payments source 2025-01-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.07 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.07 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.58 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.56 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.52 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.62 · Open Payments source 2025-04-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.40 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.92 · Open Payments source 2025-05-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.77 · Open Payments source 2025-06-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.31 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,147.50 · Open Payments source 2025-06-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.79 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.80 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.90 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.61 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.05 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-07-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.78 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.68 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.94 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.65 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.80 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.06 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,295.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $281.40 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.11 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-08-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.95 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.77 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.10 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.15 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.61 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-09-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.55 · Open Payments source 2025-09-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.01 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.85 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.24 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.30 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $61.60 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.40 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $151.20 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.60 · Open Payments source 2025-09-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.17 · Open Payments source 2025-09-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.13 · Open Payments source 2025-09-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.52 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-10-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-10-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.20 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $543.37 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.43 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.29 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $78.90 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $161.00 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.35 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.27 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.07 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.92 · Open Payments source 2025-11-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.45 · Open Payments source 2025-11-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.29 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $158.90 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.20 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.90 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.19 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.65 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.80 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $263.90 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.20 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.75 · Open Payments source 2025-12-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.86 · Open Payments source 2025-12-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.39 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $245.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.65 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $765.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $765.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$3,157.57	16	2025
Source payment records 2025-01-15 · E.R. Squibb & Sons, L.L.C. · $115.99 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $8.40 · Open Payments source 2025-02-14 · E.R. Squibb & Sons, L.L.C. · $9.31 · Open Payments source 2025-03-10 · E.R. Squibb & Sons, L.L.C. · $85.76 · Open Payments source 2025-03-13 · E.R. Squibb & Sons, L.L.C. · $11.11 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $96.31 · Open Payments source 2025-06-11 · E.R. Squibb & Sons, L.L.C. · $50.54 · Open Payments source 2025-09-23 · E.R. Squibb & Sons, L.L.C. · $16.45 · Open Payments source 2025-10-02 · E.R. Squibb & Sons, L.L.C. · $3.95 · Open Payments source 2025-10-22 · E.R. Squibb & Sons, L.L.C. · $15.44 · Open Payments source 2025-11-19 · E.R. Squibb & Sons, L.L.C. · $38.37 · Open Payments source 2025-11-25 · E.R. Squibb & Sons, L.L.C. · $161.66 · Open Payments source 2025-12-11 · E.R. Squibb & Sons, L.L.C. · $925.00 · Open Payments source 2025-12-15 · E.R. Squibb & Sons, L.L.C. · $1,036.00 · Open Payments source 2025-12-15 · E.R. Squibb & Sons, L.L.C. · $555.00 · Open Payments source 2025-12-17 · E.R. Squibb & Sons, L.L.C. · $28.28 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$614.93	38	2025
Source payment records 2025-01-16 · Neurocrine BioSciences, Inc. · $25.83 · Open Payments source 2025-01-29 · Neurocrine BioSciences, Inc. · $18.98 · Open Payments source 2025-02-07 · Neurocrine BioSciences, Inc. · $15.20 · Open Payments source 2025-02-27 · Neurocrine BioSciences, Inc. · $20.33 · Open Payments source 2025-02-28 · Neurocrine BioSciences, Inc. · $13.03 · Open Payments source 2025-02-28 · Neurocrine BioSciences, Inc. · $0.22 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $17.70 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $15.63 · Open Payments source 2025-03-25 · Neurocrine BioSciences, Inc. · $12.37 · Open Payments source 2025-03-27 · Neurocrine BioSciences, Inc. · $17.57 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $17.65 · Open Payments source 2025-04-21 · Neurocrine BioSciences, Inc. · $19.31 · Open Payments source 2025-05-02 · Neurocrine BioSciences, Inc. · $25.09 · Open Payments source 2025-05-14 · Neurocrine BioSciences, Inc. · $0.20 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $12.74 · Open Payments source 2025-05-20 · Neurocrine BioSciences, Inc. · $17.58 · Open Payments source 2025-06-05 · Neurocrine BioSciences, Inc. · $18.03 · Open Payments source 2025-06-12 · Neurocrine BioSciences, Inc. · $23.57 · Open Payments source 2025-06-18 · Neurocrine BioSciences, Inc. · $17.06 · Open Payments source 2025-06-18 · Neurocrine BioSciences, Inc. · $0.18 · Open Payments source 2025-06-26 · Neurocrine BioSciences, Inc. · $20.59 · Open Payments source 2025-06-30 · Neurocrine BioSciences, Inc. · $10.96 · Open Payments source 2025-07-31 · Neurocrine BioSciences, Inc. · $35.29 · Open Payments source 2025-08-12 · Neurocrine BioSciences, Inc. · $20.58 · Open Payments source 2025-08-14 · Neurocrine BioSciences, Inc. · $15.80 · Open Payments source 2025-09-15 · Neurocrine BioSciences, Inc. · $18.70 · Open Payments source 2025-09-30 · Neurocrine BioSciences, Inc. · $21.32 · Open Payments source 2025-10-10 · Neurocrine BioSciences, Inc. · $16.07 · Open Payments source 2025-10-10 · Neurocrine BioSciences, Inc. · $0.20 · Open Payments source 2025-10-15 · Neurocrine BioSciences, Inc. · $15.46 · Open Payments source 2025-10-29 · Neurocrine BioSciences, Inc. · $17.36 · Open Payments source 2025-10-29 · Neurocrine BioSciences, Inc. · $0.22 · Open Payments source 2025-11-07 · Neurocrine BioSciences, Inc. · $26.06 · Open Payments source 2025-11-13 · Neurocrine BioSciences, Inc. · $29.31 · Open Payments source 2025-12-03 · Neurocrine BioSciences, Inc. · $12.81 · Open Payments source 2025-12-11 · Neurocrine BioSciences, Inc. · $13.64 · Open Payments source 2025-12-11 · Neurocrine BioSciences, Inc. · $0.32 · Open Payments source 2025-12-18 · Neurocrine BioSciences, Inc. · $31.97 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$436.71	24	2025
Source payment records 2025-01-08 · Otsuka America Pharmaceutical, Inc. · $14.45 · Open Payments source 2025-01-17 · Otsuka America Pharmaceutical, Inc. · $15.39 · Open Payments source 2025-01-23 · Otsuka America Pharmaceutical, Inc. · $16.64 · Open Payments source 2025-02-25 · Otsuka America Pharmaceutical, Inc. · $12.23 · Open Payments source 2025-03-18 · Otsuka America Pharmaceutical, Inc. · $13.33 · Open Payments source 2025-03-18 · Otsuka America Pharmaceutical, Inc. · $0.87 · Open Payments source 2025-03-28 · Lundbeck LLC · $17.04 · Open Payments source 2025-04-08 · Otsuka America Pharmaceutical, Inc. · $23.22 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $12.39 · Open Payments source 2025-04-15 · Otsuka America Pharmaceutical, Inc. · $8.34 · Open Payments source 2025-04-30 · Otsuka America Pharmaceutical, Inc. · $14.72 · Open Payments source 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $10.57 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $14.19 · Open Payments source 2025-06-20 · Lundbeck LLC · $13.94 · Open Payments source 2025-08-05 · Otsuka America Pharmaceutical, Inc. · $1.17 · Open Payments source 2025-08-05 · Otsuka America Pharmaceutical, Inc. · $16.62 · Open Payments source 2025-08-20 · Lundbeck LLC · $15.71 · Open Payments source 2025-08-27 · Otsuka America Pharmaceutical, Inc. · $17.22 · Open Payments source 2025-09-19 · Otsuka America Pharmaceutical, Inc. · $22.47 · Open Payments source 2025-10-01 · Otsuka America Pharmaceutical, Inc. · $9.58 · Open Payments source 2025-11-04 · Otsuka America Pharmaceutical, Inc. · $8.93 · Open Payments source 2025-11-04 · Otsuka America Pharmaceutical, Inc. · $125.50 · Open Payments source 2025-11-22 · Otsuka America Pharmaceutical, Inc. · $15.63 · Open Payments source 2025-12-10 · Otsuka America Pharmaceutical, Inc. · $16.56 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$372.94	24	2025
Source payment records 2025-01-03 · Janssen Pharmaceuticals, Inc · $6.86 · Open Payments source 2025-02-03 · Janssen Pharmaceuticals, Inc · $7.12 · Open Payments source 2025-03-27 · Janssen Pharmaceuticals, Inc · $21.80 · Open Payments source 2025-04-16 · Janssen Pharmaceuticals, Inc · $18.17 · Open Payments source 2025-05-19 · Janssen Pharmaceuticals, Inc · $21.03 · Open Payments source 2025-06-11 · Janssen Pharmaceuticals, Inc · $23.99 · Open Payments source 2025-07-11 · Janssen Pharmaceuticals, Inc · $7.84 · Open Payments source 2025-08-08 · Janssen Pharmaceuticals, Inc · $8.91 · Open Payments source 2025-08-15 · Janssen Pharmaceuticals, Inc · $36.08 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $7.10 · Open Payments source 2025-09-05 · Janssen Pharmaceuticals, Inc · $7.47 · Open Payments source 2025-09-09 · Janssen Pharmaceuticals, Inc · $17.10 · Open Payments source 2025-09-12 · Janssen Pharmaceuticals, Inc · $7.44 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $25.63 · Open Payments source 2025-10-09 · Janssen Pharmaceuticals, Inc · $26.33 · Open Payments source 2025-10-17 · Janssen Pharmaceuticals, Inc · $8.11 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $7.47 · Open Payments source 2025-10-27 · Janssen Pharmaceuticals, Inc · $22.31 · Open Payments source 2025-11-07 · Janssen Pharmaceuticals, Inc · $8.63 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $8.52 · Open Payments source 2025-11-18 · Janssen Pharmaceuticals, Inc · $23.62 · Open Payments source 2025-12-02 · Janssen Pharmaceuticals, Inc · $17.46 · Open Payments source 2025-12-12 · Janssen Pharmaceuticals, Inc · $6.73 · Open Payments source 2025-12-16 · Janssen Pharmaceuticals, Inc · $27.22 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$253.44	11	2025
Source payment records 2025-01-09 · Vanda Pharmaceuticals Inc. · $29.42 · Open Payments source 2025-01-30 · Vanda Pharmaceuticals Inc. · $32.70 · Open Payments source 2025-02-14 · Vanda Pharmaceuticals Inc. · $29.80 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $18.64 · Open Payments source 2025-06-01 · Vanda Pharmaceuticals Inc. · $17.23 · Open Payments source 2025-06-18 · Vanda Pharmaceuticals Inc. · $22.44 · Open Payments source 2025-07-02 · Vanda Pharmaceuticals Inc. · $21.85 · Open Payments source 2025-08-06 · Vanda Pharmaceuticals Inc. · $7.78 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $20.40 · Open Payments source 2025-10-30 · Vanda Pharmaceuticals Inc. · $36.12 · Open Payments source 2025-11-19 · Vanda Pharmaceuticals Inc. · $17.06 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$173.85	20	2025
Source payment records 2025-01-14 · Otsuka America Pharmaceutical, Inc. · $9.77 · Open Payments source 2025-02-13 · Otsuka America Pharmaceutical, Inc. · $13.70 · Open Payments source 2025-03-04 · Otsuka America Pharmaceutical, Inc. · $1.72 · Open Payments source 2025-03-04 · Otsuka America Pharmaceutical, Inc. · $8.68 · Open Payments source 2025-03-25 · Otsuka America Pharmaceutical, Inc. · $12.99 · Open Payments source 2025-04-17 · Otsuka America Pharmaceutical, Inc. · $7.73 · Open Payments source 2025-05-08 · Otsuka America Pharmaceutical, Inc. · $7.46 · Open Payments source 2025-05-15 · Otsuka America Pharmaceutical, Inc. · $19.62 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $8.21 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $2.49 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $17.38 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $0.95 · Open Payments source 2025-09-12 · Otsuka America Pharmaceutical, Inc. · $15.52 · Open Payments source 2025-09-13 · Otsuka America Pharmaceutical, Inc. · $2.13 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $2.25 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $10.95 · Open Payments source 2025-11-20 · Otsuka America Pharmaceutical, Inc. · $15.52 · Open Payments source 2025-11-21 · Otsuka America Pharmaceutical, Inc. · $2.17 · Open Payments source 2025-12-18 · Otsuka America Pharmaceutical, Inc. · $12.75 · Open Payments source 2025-12-18 · Otsuka America Pharmaceutical, Inc. · $1.86 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$173.85	20	2025
Source payment records 2025-01-14 · Otsuka America Pharmaceutical, Inc. · $9.77 · Open Payments source 2025-02-13 · Otsuka America Pharmaceutical, Inc. · $13.70 · Open Payments source 2025-03-04 · Otsuka America Pharmaceutical, Inc. · $1.72 · Open Payments source 2025-03-04 · Otsuka America Pharmaceutical, Inc. · $8.68 · Open Payments source 2025-03-25 · Otsuka America Pharmaceutical, Inc. · $12.99 · Open Payments source 2025-04-17 · Otsuka America Pharmaceutical, Inc. · $7.73 · Open Payments source 2025-05-08 · Otsuka America Pharmaceutical, Inc. · $7.46 · Open Payments source 2025-05-15 · Otsuka America Pharmaceutical, Inc. · $19.62 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $8.21 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $2.49 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $17.38 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $0.95 · Open Payments source 2025-09-12 · Otsuka America Pharmaceutical, Inc. · $15.52 · Open Payments source 2025-09-13 · Otsuka America Pharmaceutical, Inc. · $2.13 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $2.25 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $10.95 · Open Payments source 2025-11-20 · Otsuka America Pharmaceutical, Inc. · $15.52 · Open Payments source 2025-11-21 · Otsuka America Pharmaceutical, Inc. · $2.17 · Open Payments source 2025-12-18 · Otsuka America Pharmaceutical, Inc. · $12.75 · Open Payments source 2025-12-18 · Otsuka America Pharmaceutical, Inc. · $1.86 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$163.99	11	2025
Source payment records 2025-01-27 · Teva Pharmaceuticals USA, Inc. · $16.06 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $12.91 · Open Payments source 2025-06-18 · Teva Pharmaceuticals USA, Inc. · $13.05 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $17.67 · Open Payments source 2025-09-18 · Teva Pharmaceuticals USA, Inc. · $12.94 · Open Payments source 2025-10-15 · Teva Pharmaceuticals USA, Inc. · $11.69 · Open Payments source 2025-10-31 · Teva Pharmaceuticals USA, Inc. · $11.69 · Open Payments source 2025-11-17 · Teva Pharmaceuticals USA, Inc. · $21.54 · Open Payments source 2025-11-24 · Teva Pharmaceuticals USA, Inc. · $14.35 · Open Payments source 2025-12-15 · Teva Pharmaceuticals USA, Inc. · $15.38 · Open Payments source 2025-12-15 · Teva Pharmaceuticals USA, Inc. · $16.71 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$152.09	7	2025
Source payment records 2025-01-13 · Teva Pharmaceuticals USA, Inc. · $16.54 · Open Payments source 2025-04-14 · Teva Pharmaceuticals USA, Inc. · $23.45 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $28.73 · Open Payments source 2025-07-21 · Teva Pharmaceuticals USA, Inc. · $24.73 · Open Payments source 2025-09-19 · Teva Pharmaceuticals USA, Inc. · $1.92 · Open Payments source 2025-09-22 · Teva Pharmaceuticals USA, Inc. · $24.59 · Open Payments source 2025-11-10 · Teva Pharmaceuticals USA, Inc. · $32.13 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$150.05	13	2025
Source payment records 2025-03-05 · Alkermes, Inc. · $13.35 · Open Payments source 2025-04-11 · Alkermes, Inc. · $15.05 · Open Payments source 2025-05-07 · Alkermes, Inc. · $7.35 · Open Payments source 2025-06-03 · Alkermes, Inc. · $12.31 · Open Payments source 2025-06-18 · Alkermes, Inc. · $11.80 · Open Payments source 2025-07-30 · Alkermes, Inc. · $14.50 · Open Payments source 2025-08-14 · Alkermes, Inc. · $11.04 · Open Payments source 2025-10-21 · Alkermes, Inc. · $3.83 · Open Payments source 2025-10-21 · Alkermes, Inc. · $1.54 · Open Payments source 2025-11-06 · Alkermes, Inc. · $11.09 · Open Payments source 2025-11-26 · Alkermes, Inc. · $11.51 · Open Payments source 2025-12-12 · Alkermes, Inc. · $19.47 · Open Payments source 2025-12-18 · Alkermes, Inc. · $17.21 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$150.05	13	2025
Source payment records 2025-03-05 · Alkermes, Inc. · $13.35 · Open Payments source 2025-04-11 · Alkermes, Inc. · $15.05 · Open Payments source 2025-05-07 · Alkermes, Inc. · $7.35 · Open Payments source 2025-06-03 · Alkermes, Inc. · $12.31 · Open Payments source 2025-06-18 · Alkermes, Inc. · $11.80 · Open Payments source 2025-07-30 · Alkermes, Inc. · $14.50 · Open Payments source 2025-08-14 · Alkermes, Inc. · $11.04 · Open Payments source 2025-10-21 · Alkermes, Inc. · $3.83 · Open Payments source 2025-10-21 · Alkermes, Inc. · $1.54 · Open Payments source 2025-11-06 · Alkermes, Inc. · $11.09 · Open Payments source 2025-11-26 · Alkermes, Inc. · $11.51 · Open Payments source 2025-12-12 · Alkermes, Inc. · $19.47 · Open Payments source 2025-12-18 · Alkermes, Inc. · $17.21 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$127.57	7	2025
Source payment records 2025-02-12 · Axsome Therapeutics, Inc. · $14.75 · Open Payments source 2025-03-11 · Axsome Therapeutics, Inc. · $19.69 · Open Payments source 2025-04-15 · Axsome Therapeutics, Inc. · $18.98 · Open Payments source 2025-05-07 · Axsome Therapeutics, Inc. · $19.09 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $15.77 · Open Payments source 2025-10-24 · Axsome Therapeutics, Inc. · $19.35 · Open Payments source 2025-11-13 · Axsome Therapeutics, Inc. · $19.94 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$110.56	4	2025
Source payment records 2025-01-09 · Vanda Pharmaceuticals Inc. · $29.42 · Open Payments source 2025-01-30 · Vanda Pharmaceuticals Inc. · $32.70 · Open Payments source 2025-02-14 · Vanda Pharmaceuticals Inc. · $29.80 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $18.64 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$80.09	4	2025
Source payment records 2025-05-30 · ABBVIE INC. · $24.10 · Open Payments source 2025-06-14 · ABBVIE INC. · $19.93 · Open Payments source 2025-08-23 · ABBVIE INC. · $14.24 · Open Payments source 2025-10-02 · ABBVIE INC. · $21.82 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$40.60	2	2025
Source payment records 2025-09-02 · Janssen Pharmaceuticals, Inc · $19.65 · Open Payments source 2025-10-31 · Janssen Pharmaceuticals, Inc · $20.95 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$36.65	2	2025
Source payment records 2025-01-29 · Supernus Pharmaceuticals, Inc. · $22.76 · Open Payments source 2025-02-27 · Supernus Pharmaceuticals, Inc. · $13.89 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$17.29	1	2025
Source payment records 2025-04-02 · Takeda Pharmaceuticals U.S.A., Inc. · $17.29 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
CAPLYTA caplyta	2025	Caplyta	2024	79	exact normalized	Medicare Part D
FANAPT fanapt	2025	Fanapt	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	89 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	114	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	22 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	42 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	42	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	79	15
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	79	15
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	89	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	114	16
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	114	16
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192	Austedo · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	FANAPT open payments reported associated product	CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535	Fanapt · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Risperidone	Risperidone	215	22
Quetiapine Fumarate	Quetiapine Fumarate	212	30
Sertraline Hcl	Sertraline Hcl	193	29
Trazodone Hcl	Trazodone Hcl	190	28
Duloxetine Hcl	Duloxetine Hcl	152	19
Olanzapine	Olanzapine	145	19
Mirtazapine	Mirtazapine	137	22
Clozapine	Clozapine	125	suppressed
Aripiprazole	Aripiprazole	122	18
Escitalopram Oxalate	Escitalopram Oxalate	117	19
Rexulti	Brexpiprazole	114	16
Divalproex Sodium	Divalproex Sodium	111	19
Fluoxetine Hcl	Fluoxetine Hcl	98	suppressed
Bupropion Xl	Bupropion Hcl	91	11
Invega Sustenna	Paliperidone Palmitate	89	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	81	11
Hydroxyzine Hcl	Hydroxyzine Hcl	80	16
Caplyta	Lumateperone Tosylate	79	15
Clonazepam	Clonazepam	76	13
Buspirone Hcl	Buspirone Hcl	75	16
Lamotrigine	Lamotrigine	70	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	63	suppressed
Divalproex Sodium Er	Divalproex Sodium	61	suppressed
Prazosin Hcl	Prazosin Hcl	61	suppressed
Haloperidol	Haloperidol	59	suppressed
Citalopram Hbr	Citalopram Hydrobromide	57	suppressed
Topiramate	Topiramate	52	suppressed
Lorazepam	Lorazepam	45	suppressed
Vraylar	Cariprazine Hcl	42	suppressed
Benztropine Mesylate	Benztropine Mesylate	40	12
Paliperidone Er	Paliperidone	40	suppressed
Ropinirole Hcl	Ropinirole Hcl	39	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	38	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	38	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Lurasidone Hcl	Lurasidone Hcl	32	suppressed
Gabapentin	Gabapentin	31	suppressed
Alprazolam	Alprazolam	29	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	26	suppressed
Doxepin Hcl	Doxepin Hcl	25	suppressed
Ramelteon	Ramelteon	24	suppressed
Trintellix	Vortioxetine Hydrobromide	22	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	20	suppressed
Lithium Carbonate	Lithium Carbonate	20	suppressed
Oxcarbazepine	Oxcarbazepine	20	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	20	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	16	suppressed
Clomipramine Hcl	Clomipramine Hcl	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Austedo	Deutetrabenazine	13	suppressed
Diazepam	Diazepam	13	suppressed
Imipramine Hcl	Imipramine Hcl	13	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	13	suppressed
Vilazodone Hcl	Vilazodone Hcl	13	suppressed
Fanapt	Iloperidone	12	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$57,327.21 · 303 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, LYBALVI, Qelbree, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VRAYLAR	9	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Caplyta play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error